Companies · AZN
AstraZeneca
AI-generated · informational only · not investment advice · verify before relying.
Latest analysis
Updated Sep 1, 2026
AstraZeneca admits 10,072 ordinary shares under employee share schemes; FY2025 revenue $58.74B (+8.6% YoY).
This 6-K reports routine admission of 10,072 shares to the London Stock Exchange under AstraZeneca's existing employee share scheme block admission dated January 2021. The filing contains no material business updates, pipeline developments, guidance changes, or strategic announcements. It is a compliance notification required under UK listing regulations (POATRs PRM 1.6.4R) covering share issuances between August 1–31, 2026. Total ordinary shares outstanding post-admission: 1,551,043,461.
Tone: neutralRevenue
$58.7B
AZN 20-F · FY 2025
Revenue FY2024
$54.1B
Founded
1992
Headquarters
Cambridge
Profile
AZN 20-F Item 4.B · Feb 24, 2026AstraZeneca PLC is a global, innovation-driven biopharmaceutical company focused on the discovery, development, and commercialisation of prescription medicines across Oncology, Cardiovascular Renal & Metabolism, Respiratory & Immunology, Vaccines & Immune Therapies, and Rare Disease. The company operates in over 100 countries and markets medicines to millions of patients worldwide. It was formed through the 1999 merger of Astra of Sweden and Zeneca Group PLC, and significantly expanded into rare disease through the 2021 acquisition of Alexion.
Read filing description ↓ Collapse description ↑
AstraZeneca PLC was incorporated in England and Wales on June 17, 1992 and is a public limited company domiciled in the United Kingdom. The Company was formed when the pharmaceutical, agrochemical and specialty chemical businesses of Imperial Chemical Industries PLC were demerged in 1993. In 1999, the Company merged with Astra of Sweden. In 2007, the Group acquired MedImmune, a biologics and vaccines business based in the United States. In 2021, the Group acquired Alexion, a rare disease business based in the United States. AstraZeneca is a global, innovation-driven biopharmaceutical business with operations in over 100 countries and its innovative medicines are used by millions of patients worldwide. The Company's commercial portfolio spans five therapy areas: Oncology (including Tagrisso, Imfinzi, Calquence, Lynparza, Enhertu, Truqap, and Datroway); Cardiovascular, Renal & Metabolism (including Farxiga, Brilinta, Lokelma, and Wainua); Respiratory & Immunology (including Symbicort, Fasenra, Breztri, Tezspire, Saphnelo, and Airsupra); Vaccines & Immune Therapies (including Beyfortus and FluMist); and Rare Disease (including Ultomiris, Soliris, Strensiq, and Koselugo). The company reports revenues across four geographic regions: the US, Emerging Markets, Europe, and Established Rest of World.
Primary products
- Tagrisso (osimertinib)
- Imfinzi (durvalumab)
- Calquence (acalabrutinib)
- Lynparza (olaparib)
- Enhertu (trastuzumab deruxtecan)
- Truqap (capivasertib)
Business segments
End markets
Geographies
Revenue commentary · FY 2025
Reported in USD. Total Revenue increased from $54,073 million in 2024 to $58,739 million in 2025, driven by strong Product Sales growth across all therapy areas, particularly Oncology, and growth in Alliance Revenue.
The rest of AZN is for subscribers
Analysis, signals, diligence answers, M&A activity and every quote, each citing the filing it came from.